Hers vs Mochi Health: Which GLP-1 Provider Is Better?

By Iacob Pastina, Independent Researcher

48 providers verified independently·Independent research·How we rank →

Mochi Health beats Hers overall, scoring 7.7/10 vs 7.3/10. Mochi Health is more affordable at $178/mo vs $199/mo. Choose Hers for women who want brand-name wegovy (injection or pill) at $149. Choose Mochi Health for users who want a tech-forward platform with app-based tracki.

A side-by-side comparison of Hers and Mochi Health covering pricing, scores, medication types, insurance, and more to help you decide.

Hers

#35 of 48

7.3/10

The women's health arm of Hims & Hers Health (NYSE: HIMS). In 2026 Hers signed a direct Novo Nordisk partnership adding FDA-approved Wegovy (pen and pill) at $149/mo and Zepbound via the Lilly partnership — alongside their existing compounded semaglutide and new compounded tirzepatide programs.

Visit Hers

Higher Rated

Mochi Health

#20 of 48

7.7/10

Tech-forward GLP-1 platform with a sleek app for tracking progress, medications, and provider communications.

Visit Mochi Health

Feature	Hers	Mochi Health
Our Score	7.3/10	7.7/10
Starting Price	$199/mo	$178/mo
Medication Type	Both	Compounded
Insurance Accepted	No	No
Best For	Women who want brand-name Wegovy (injection or pill) at $149/mo via the 2026 Novo Nordisk partnership, or a compounded semaglutide option from a publicly traded telehealth brand	Users who want a tech-forward platform with app-based tracking
Ranking	#35	#20

Pros & Cons Compared

Hers

Pros

+2026 Novo Nordisk partnership — FDA-approved Wegovy pen and Wegovy oral pill from $149/mo, one of the lowest brand-name GLP-1 prices on the market
+Zepbound access via the Lilly/Hims-Hers partnership announced 2026
+Publicly traded company (NYSE: HIMS) with strong financial backing and regulatory compliance
+Broader women's health platform — integrates weight loss with hormonal, skin, and wellness services

Cons

−Membership + medication are billed separately ($39 first month / $149 ongoing membership) — watch the all-in math
−Generic support experience — large patient volume means less personalized attention
−Compounded pricing starts at $199/mo but stepped pricing applies at higher doses
−Zepbound access priced at ~$1,899/mo (brand cash) via the Lilly partnership — read as access, not value

Mochi Health

Pros

+Flat $99/mo semaglutide at ALL dose levels — saves $100-200/mo vs competitors who charge more at higher doses
+4 semaglutide formats: injection, oral tablet, oral drops, and microdose — the most delivery options of any platform
+Registered dietitians included alongside physicians — not just medication, but nutritional support
+Both compounded and brand-name medications available (Ozempic, Wegovy, Mounjaro, Zepbound, Rybelsus)

Cons

−Separate $79/mo membership fee makes the real cost ~$178/mo for semaglutide, not the advertised $99
−No refunds for payments made over 30 days ago — limited consumer protection window
−Relatively new company (founded 2022) with less track record than established platforms

Our Verdict

Mochi Health edges out Hers with a score of 7.7/10 vs 7.3/10. If budget is your priority, Mochi Health starts at $178/mo compared to Hers's $199/mo. Hers offers both brand-name and compounded medications, giving you more flexibility. Choose Hers if you want: women who want brand-name wegovy (injection or pill) at $149/mo via the 2026 novo nordisk partnership, or a compounded semaglutide option from a publicly traded telehealth brand. Choose Mochi Health if you want: users who want a tech-forward platform with app-based tracking.

Still undecided? Editor's #1 Overall Pick

Embody

$299/mo · 7.3/10 · Compounded

If neither Hers nor Mochi Health feels like the right fit, our overall #1 pick across all 48 GLP-1 telehealth providers is Embody — strongest balance of clinical oversight, transparent pricing, and verified availability.

Visit Embody→Read our full Embody review